A Silver Lining In Lilly’s Solanezumab Alzheimer’s Failure?
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug fails all primary endpoints in two Phase III studies, following in the footsteps of Pfizer/Janssen’s bapineuzumab. But Lilly points to a secondary signal in pooled data as a sign of some effect on cognitive decline.